Immunogenicity and safety of a tetravalent dengue vaccine during a five-year follow-up period

Trials in Vaccinology

Volumn 4, Issue , 2015, Pages 19-23

  Capeding, Maria Rosario ^a   Laot, Thelma M ^b   Boaz, Mark ^c   Wartel, T Anh ^d   Crevat, Denis ^c  

^a RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^b Sanofi Pasteur   (Philippines)

^c SANOFI PASTEUR   (France)

^d Sanofi Aventis   (Singapore)

Author keywords

Antibody; Dengue; Safety; Tetravalent vaccine; Vaccination

Indexed keywords

DENGUE VACCINE; NEUTRALIZING ANTIBODY; TETRAVALENT DENGUE VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; ATTENUATION; CHILD; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; GEOMETRY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MYOFASCIAL PAIN; PHILIPPINES; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; TYPHOID FEVER; VIROLOGY; VIRUS NEUTRALIZATION; VOMITING; WILD TYPE;

EID: 84927155026     PISSN: None     EISSN: 18794378     Source Type: Journal    
DOI: 10.1016/j.trivac.2015.03.002     Document Type: Article

References (16)

1. World Health Organization. Global strategy for dengue prevention and control: 2012-2020. Available from: < http://www.who.int/denguecontrol/9789241504034/en/ > (ACCESSED 8 January 2015), 2012.
2. A. Sabchareon, D. Wallace, and C. Sirivichayakul Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial Lancet 380 9853 2012 1559 1567
3. J. Poo, F. Galan, R. Forrat, B. Zambrano, J. Lang, and G.H. Dayan Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity Pediatr. Infect. Dis. J. 30 2011 e9 e17
4. C. Johnson, M. Thakur, M. Boaz, G. Dayan, Immunogenicity and safety of three formulations of a tetravalent dengue vaccine candidate among healthy adults in the US Presented at: IDweek 2012, San Diego, USA, 2012. Available from: < https://idsa.confex.com/idsa/2012/webprogram/Paper37442.html > (Assessed 08 January 2015).
5. D. Morrison, T.J. Legg, C.W. Billings, R. Forrat, S. Yoksan, and J. Lang A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults J. Infect. Dis. 201 3 2010 370 377
6. C.F. Lanata, T. Andrade, and A.I. Gil Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru Vaccine 30 41 2012 5935 5941
7. Y.S. Leo, A. Wilder-Smith, and S. Archuleta Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: phase II randomized controlled trial in Singapore Hum. Vaccine Immunother. 8 9 2012 1259 1271
8. N.H. Tran, C.Q. Luong, and T.Q.H. Vu Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD- TDV) in healthy Vietnamese adults and children J. Vaccines Vaccine 3 7 2012 1000162
9. L. Villar, G.H. Dayan, and J.L. Arredondo-Garcia Efficacy of a tetravalent dengue vaccine in children in Latin America N. Engl. J. Med. 372 2 2015 113 123
10. M.R. Capeding, N.H. Tran, and S.R. Hadinegoro Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial Lancet 384 9951 2014 1358 1365
11. R.Z. Capeding, I.A. Luna, and E. Bomasang Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines Vaccine 29 22 2011 3863 3872
12. T.M. Timiryasova, M.I. Bonaparte, P. Luo, R. Zedar, B.T. Hu, and S.W. Hildreth Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development Am. J. Trop. Med. Hyg. 88 5 2013 962 970
13. I.K. Yoon, A.L. Rothman, and D. Tannitisupawong i mildly symptomatic viremic dengue virus infections in rural Thai schools and villages J. Infect. Dis. 206 3 2012 389 398
14. T.P. Endy, S. Chunsuttiwat, and A. Nisalak Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand Am. J. Epidemiol. 156 1 2002 40 51
15. M. Montoya, L. Gresh, and J.C. Mercado Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year PLoS Negl. Trop. Dis. 7 8 2013 e2357
16. S.J. Thomas, A. Nisalak, and K.B. Anderson Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance Am. J. Trop. Med. Hyg. 81 5 2009 825 833